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Abstract This randomised feasibility study aimed to examine
the clinical and biomechanical effects of functional foot ortho-
ses (FFOs) in the treatment of midfoot osteoarthritis (OA) and
the feasibility of conducting a full randomised controlled trial.
Participants with painful, radiographically confirmed midfoot
OAwere recruited and randomised to receive either FFOs or a
sham control orthosis. Feasibility measures included recruit-
ment and attrition rates, practicality of blinding and adherence
rates. Clinical outcome measures were: change from baseline
to 12 weeks for severity of pain (numerical rating scale), foot
function (Manchester Foot Pain and Disability Index) and
patient global impression of change scale. To investigate the
biomechanical effect of foot orthoses, in-shoe foot kinematics
and plantar pressures were evaluated at 12 weeks. Of the 119
participants screened, 37 were randomised and 33 completed
the study (FFO=18, sham=15). Compliance with foot ortho-
ses and blinding of the intervention was achieved in three
quarters of the group. Both groups reported improvements in
pain, function and global impression of change; the FFO
group reporting greater improvements compared to the sham
group. The biomechanical outcomes indicated the FFO group
inverted the hindfoot and increased midfoot maximum plantar
force compared to the sham group. The present findings sug-
gest FFOs worn over 12 weeks may provide detectable clini-
cal and biomechanical benefits compared to sham orthoses.
This feasibility study provides useful clinical, biomechanical
and statistical information for the design and implementation
of a definitive randomised controlled trial to evaluate the ef-
fectiveness of FFOs in treating painful midfoot OA.
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Introduction
Osteoarthritis (OA) is a common cause of joint pain and dis-
ability [1–3]. Previous population studies have suggested that
the most common site for OA in the foot is the first
metatarsophalangeal joint (prevalence of approximately
22 %), with midfoot OA reported as being relatively uncom-
mon (prevalence of 3.8 %) [4, 5]. Using a recently developed
foot atlas, which includes the first metatarsophalangeal joint,
and medial midfoot joints (first metarso-cuneiform joint, sec-
ond metatarso-cuneiform joint, navicular-cueniform joint and
talo-navicular joint), two large population studies have
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demonstrated that medial midfoot OA is more prevalent than
previously reported [6, 7]. The prevalence of medial midfoot
OA in an older population was 88% (compared to 95% in the
metatarsophalangeal joint); while in a younger community
study, the prevalence of medial midfoot OAwas 7.8 % (com-
pared to 6.8 % in the metatarsophalangeal joint), contributing
to the prevalence of disabling foot pain [8]. Compared to the
hip and knee OA, there are few studies investigating the po-
tential interventions for midfoot OA.
Midfoot OA is associated with movement impairment,
structural deformity and increased foot pressures [9–11].
Modification of these factors, via functional foot orthoses
(FFOs), provides a possible mechanism for biomechanically
based clinical treatments. Two previous clinical midfoot OA
studies have demonstrated improvements in pain and func-
tion following the use of FFOs over 4 weeks [12] and
6 months [13], although neither employed a randomised
placebo or sham control. NICE guidelines [14] recommend
that foot orthoses should be considered as an adjunct therapy
for OA despite the lack of quality randomised controlled
trials (RCTs) as they carry minimal risk. This study was
undertaken under the auspices of the Arthritis Research
UK Clinical Studies Group for Osteoarthritis and Crystal
Diseases to examine the feasibility of conducting a definitive
RCT (Orthoses in Foot Function and Loading in OA Dis-
ease: OFFLOAD). The aim of this feasibility study was to
determine whether functional foot orthoses have the poten-
tial to help painful and disabling midfoot osteoarthritis. This
was addressed through three objectives: (1) to explore the
key methodological issues for a future RCT, (2) to establish
whether FFOs improve midfoot OA-related pain and func-
tion over 12 weeks and (3) to explore FFOs alter biome-
chanical outcomes (hindfoot kinematics and midfoot forces)
compared to a sham device.
Materials and methods
Study design
The study was a double-blind, two-arm parallel group
randomised controlled feasibility study. Participants were
randomised at baseline to receive either a pair of ‘active’ FFOs
(see Fig. 1a) in the intervention group or sham orthoses (see
Fig. 1b) in the control group (please see Supplementary file
for details). The term ‘active FFOs’ in the context of this
study relates to three functional features; a contoured semi-
rigid shell, a stabilising cupped heel and the use of heel
wedging to influence foot position. Randomisation was con-
ducted on a 1:1 basis, with no stratification by a blinded
member of the study team (RAW), according to a random
number algorithm contained in pre-sealed envelopes [15].
The study was designed to recruit 20 participants in each
group [16], with a follow-up period of 12 weeks to allow a
reasonable clinical assessment and feasibility of compliance
and attrition to be evaluated.
Participants
Participants were recruited from a community musculoskele-
tal service. Potential participants were verbally and clinically
screened to ensure they met inclusion/exclusion criteria.
Patient-reported medical history and medications were record-
ed by the main researcher (JH), and physician-confirmed
(from GP medical record summary) concomitant OA in the
body was recorded on a manikin by the patient. Participants
were included if they were ≥18 years of age, reported foot pain
for ≥3 months, located the foot pain within the midfoot region
by drawing the location on a foot pain manikin in predetermined
dorsal and medial regions of the foot [17] (© The University
of Manchester 2000. All rights reserved) and reported midfoot
pain occurring with or worsening immediately following
weight-bearing activities. All participants had radiographic
midfoot OA verified on weight-bearing radiographs by a mus-
culoskeletal radiologist (AG) using predetermined criteria
recommended in the La Trobe University Atlas of Foot Osteo-
arthritis [6]. Osteoarthritis-related foot pain was defined by a
score >2/10 on an 11-point numerical rating scale (NRS) for
average foot pain the last week and at least one criteria of the
foot function impairment reported on most days (Manchester
Foot Pain and Disability Index [MFPDI] [18]). Exclusion
criteria were contraindications to radiographs or gait analysis;
history of suspected or confirmed inflammatory joint disease,
neuropathy or stress fractures; history of lower limb bone and
Fig. 1 Diagram illustrating the posterior-medial view of the interventions
a functional foot orthoses and b sham
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joint surgery in the last 12 months; or existing use of over-the-
counter or prescribed foot orthoses.
To avoid breaching assumptions of statistical independence
in bilateral limb studies, one limb per participant was included
in the analyses [19]: if participants reported midfoot pain in
both feet, the most painful foot was used as the study limb. If
midfoot pain was equal in both feet, the dominant foot was
included (defined by first step initiation). Bradford NHS re-
search ethics committee approval was obtained (reference: 12/
YH/0093), and all participants provided written informed con-
sent prior to commencing the study according to the Declara-
tion of Helsinki.
Intervention
In the FFO group, participants received a pair of firm semi-
rigid FFOs (VectOrthotic® Healthy Step [Sensograph] Ltd),
which contoured into the arch and supported the midfoot with
the aim of controlling joint motion. Functional foot orthoses
were prescribed as per standard clinical practice and
customised to each participant by an experienced clinical po-
diatrist (JH) (see Fig. 1a and Supplementary file for details).
The sham group received orthoses that mimicked the appear-
ance of the active intervention but without firm midfoot support
and heel wedging (see Fig. 1b and Supplementary file). It was
hypothesised that the sham intervention had some cushioning
properties but none of the significant mechanical characteristics
of the active FFO (see Supplementary file for details) and could
be deemed a sham [20]. A footwear advice leaflet was provided
to all participants providing fitting and contact information.
Intervention blinding
In the patient information sheet, the two types of foot ortho-
ses were presented; either joint controlling or cushioning. It
was not implied which intervention was superior; only that a
fair evaluation of two types of orthoses were being tested.
Participants were blind to the treatment allocation in order to
limit assessment and expectation bias, and every attempt
was made to maintain the blind. A single researcher (JH)
was responsible for the provision of orthoses and clinical
care but was not involved in the acquisition of patient-
reported outcome measures (PROMs) at follow-up. The
preservation of blinding was formally examined by inter-
view at the end of the study.
Data capture and outcome measures
Patient-reported outcome measures
All PROMswere validated and entered by a second researcher
(RAW) who remained blinded to treatment allocation. The
clinical outcomes were change in midfoot pain and foot
disability scores from baseline to 12 weeks, chosen according
to current research and recommendations for chronic pain
trials (IMMPACT guidelines [21]):
1. A number of foot pain questions were used to examine
clinical responsiveness (for a subsequent full RCT), each
assessed using an 11-point numeric rating scale scored
from ‘no pain’ to ‘pain as bad as you can imagine’: The
anchor questions were (i) worst foot pain in the last 24 h,
(ii) average foot pain in the last 24 h, (iii) average foot
pain in the last week, (iv) average foot pain in the last
month, and (v) average foot pain while walking in the last
week [21].
2. Patient Global Impression of Change (PGIC). Participants
rated their perception of clinical improvements in foot
pain and foot pain when walking, using a 7-point Likert
scale [22].
3. Foot function, measured using the function subscale of
the MFPDI [18].
Treatment adherence
Adherence was measured daily using a self-reported diary to
record the number of hours wear per week over the 12 weeks.
Adherence was based on the mean number of hours per week,
per participant over the 12 weeks to examine between-group
differences.
Examination of intervention blinding
The success of the blinding was investigated by asking partic-
ipants at the end of the study to identify which type of inter-
vention were you provided (1) ‘controlling orthoses’, (2)
‘cushioning orthoses’ or (3) ‘do not know’. For analysis pur-
poses, participant answers were categorised into three partic-
ipant responses as correctly identified, incorrectly identified or
unknown; the proportions for each response were calculated
as a percentage.
Biomechanical outcome measures
To investigate potential biomechanical effects of the orthoses,
in-shoe plantar pressures and foot kinematics were obtained.
In order to avoid data mining, a limited number of variables
were chosen a priori and explored in this study.
The force redistribution through the midfoot was captured
using the Pedar® in-shoe system (Novel GmbH, Munich) ac-
quired at 50 Hz. During the study, the allocated orthoses were
worn in the participant’s own shoes, but to minimise the con-
founding effect of different shoe types and to accommodate
both the randomised intervention and the measuring Pedar
insole, a standardised shoe was worn by each participant
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during the laboratory acquisition. Each participant
underwent gait analysis in a standard shoe-only condition
and wearing the standard shoe plus their randomised inter-
vention in a prespecified random order. The standard shoe
consisted of an open-webbed netting upper into which slits
were cut allowing for visualisation of the markers and ac-
quisition of 3D foot kinematics (see below). The shoe also
had a flat rubber sole with no plantar contouring. After
5 min of acclimatisation, participants walked four times
across a level 10-m gait laboratory walkway at a self-
selected speed. Measures were conducted in a prespecified
random sequence and between 12 and 16 mid-pass steps
were obtained under each experimental condition.
Force data were derived using the Novel-win program (ver-
sion 0.8 Novel Win GmbH, Munich) with a Novel percent
mask dividing the study foot into three regions: hindfoot
(31 %), midfoot (33 %) and forefoot (36 %). For each partic-
ipant, the mean difference (intervention condition minus shoe-
only condition) in midfoot maximum force (% of body weight
[BW]) was calculated.
Multi-segment foot kinematics were captured using 9 mm
reflective markers attached to the skin in accordance with the
Oxford multi-segment foot model [23]. Kinematic data were
captured at 200 Hz using an eight camera motion capture
system (Vicon MX, Oxford Metrics, UK), integrated with a
force plate (Bertec Corporation, USA) capturing at 1000 Hz.
Each participant underwent gait analysis in the standard shoe-
only condition and the standard shoe plus their randomised
intervention in a prespecified random order. A static trial was
captured in a neutral reference position (Foot Posture Index
score=0 [24]). For both experimental conditions, each partic-
ipant completed six walking trials at a self-selected speed.
Kinematic data were exported to Visual 3D (C-Motion Inc.,
Rockville, MD, USA) for further analysis. Kinematic data
were filtered using a low-pass fourth-order Butterworth filter
with a cut-off frequency of 6 Hz and normalised to stance
phase centiles to enable averaging across trials and conditions.
Peak angular frontal plane motion of the hindfoot with respect
to the tibia was selected as the predefined variable of choice to
determine whether the FFO demonstrated greater constraint
on the hindfoot than the sham. At the follow-up appointment,
the mean difference between the orthoses and shoe-only con-
dition was calculated for each participant.
Statistical analysis
Statistical analysis was planned and undertaken by the Leeds
Clinical Trials Research Unit by statisticians blinded to the
intervention allocation (SB and AD). Descriptive assessment
indicated that data was sufficiently normally distributed to
report mean, standard deviation (SD) and 95 % confidence
intervals (CI). Clinical outcome measures and biomechanical
outcomes, reported as mean differences between groups (FFO
minus sham groups) with associated 95 % CI, were used to
explore the effectiveness of FFOs on pain and function. The
PGIC Likert scale was collapsed to summarise the proportion
indicating clinical improvement in each group at 6 and
12 weeks. Descriptive statistics were used to describe the fea-
sibility outcomes relating to the key methodological issues of
this feasibility study. The data was assessed and summarsied
using SAS version 9.2. (SAS Inst Inc, NC, USA).
Pre-specified minimally important differences were identi-
fied prior to study commencement. These included:
I. Improvements from baseline to 12 weeks in foot pain
using multiple NRS anchors, with the mean difference
between the two treatment groups greater than 1.5 points
[25, 26].
II. Improvements from baseline to 12 weeks of the function-
al subscale of the MFPDI, with a mean difference be-
tween treatment groups of three points or more [27].
III. At 12 weeks, the mean between-group reduction in peak
hindfoot eversion for shoe-only minus shoe-plus
randomised intervention of a mean of 2.1° or greater
[28].
IV. At 12 weeks, the mean between-group difference for
shoe-only minus shoe-plus allocated intervention in-
creasingmidfoot force by amean of 21% or greater [29].
V. The inert sham altering mean peak hindfoot inversion by
less than 2° and changing midfoot force by less than
20 %.
VI. Adequate adherence with allocated orthoses set at a
weekly average of 21 h wear for 80 % of participants
in the group.
In addition, treatment blinding, recruitment and attrition
rates were evaluated descriptively to explore the feasibility
of recruitment, retention and success of blinding participants
in a subsequent RCT.
Results
Feasibility outcome measures
Recruitment
Over 8 months, 119 potential participants were screened, of
whom 46 were eligible. Of these 46 participants, eight de-
clined and one was lost to follow-up, resulting in 37 (31 %
of screened participants, 95 % CI 23 % to 40 %) being
randomised. Nineteen participants were randomised to the
FFO group and 18 to the sham control group (see Fig. 2).
At follow-up, four participants did not complete the study
(11 % attrition rate). In the FFO group, one participant was
withdrawn due to escalating back pain and burning pains in
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her feet. In the sham group, two participants were unable to
complete the study due to sudden unrelated back pain and one
participant was lost to follow-up.
Participant demographics and clinical characteristics
Participants in the two groups were well matched for age,
although there was a higher mean BMI in the FFO group
and a slightly larger proportion of female participants com-
pared to the sham group (see Table 1). The study cohort pre-
sented with a number of common comorbidities with the most
common being hypertension and hypercholesterolemia (mean
2, range 0–9). In addition, most of the participants reported
concomitant OA in the proximal joints; medial knee OAwas
the most common location (70.3 %).
Using a foot manikin [18], all participants localised their foot
pain to the dorsal midfoot region, and six participants further
localised their pain in the medial arch region. The type of pain
was mostly described as aching or dull, and around half of
participants (57%) described a pattern of intermittent sharp pain
associated with weight-bearing activity. The median number of
OA affected midfoot joints was two. The most frequent site was
the cuneiform-second metatarsal joint (73 %), followed by the
naviculo-medial cuneiform joint (51 %), the cuneiform-first
metatarsal joint (46 %) and the talo-navicular joint (24 %).
Adherence with treatment
Participants wore their allocated orthoses a mean of 39 h per
week, and 85 % wore their allocated orthoses for >21 h. The
sham group wore their intervention an average of 18 h/week
Assessed for eligibility (n= 119) 
Excluded (n= 81) 
Not meeting inclusion criteria (n=7) 
Declined to participate (n= 8) 
Lost to follow-up (n= 1) 
Analysed  (n= 18) 
 None excluded from analysis 
Lost to follow-up (n=0)  
Discontinued intervention (n=1)  
Reason: Pain related to foot orthoses  
Allocated to FFO intervention (n=19) 
Received allocated intervention (n=19)
Lost to follow-up (n=1) 
Discontinued intervention (n= 2 ) 
Reason: Pain unrelated to foot orthoses
Allocated to sham intervention (n=18) 
Received allocated intervention (n=18)
Analysed  (n=15) 
None excluded from analysis 
Allocation
Analysis
Follow-Up
Randomized (n=37) 
Enrollment 
Fig. 2 Flow chart of participants through the study (CONSORT 2010 statement)
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longer than the FFO group (see Table 2). At 12 weeks, 93 %
of participants in the sham group reached the prespecified
mean of at least 21 h/week adherence compared to 78 % of
the FFO group.
Treatment blinding
Overall, 17 participants who completed the trial reported be-
ing unsure of their treatment allocation (FFO n=12/18; sham
n=5/15) (see Table 2). The allocated intervention was incor-
rectly identified by eight participants (FFO, n=2/18; sham, n=
6/15) and correctly identified by eight (four in each group).
Combining the number who could not identify the type of
intervention (n=17) with those who incorrectly identified the
intervention (n=8), blinding was successfully achieved in
most of the participants (n=25/33) with only minor differ-
ences between the groups (FFO=14/18, sham=11/15).
Clinical outcome measures
The FFO group demonstrated a greater reduction in mean
worst-rated foot pain in the previous 24 h (−1.4, 95 % CI
−3.5 to 0.7) and a greater reduction in the functional subscale
of the MFPDI (−1.4, 95 % CI −4.1 to 1.4) compared to the
sham group (see Table 2). Both groups reported improve-
ments in foot pain after 12 weeks (proportion of participants
reporting improvement using PGIC scale); FFO=83.4 %;
sham=46.6 %, demonstrating a between-group mean differ-
ence of 36.8 % (95 % CI 6.1 to 67.2). The results of the
additional anchoring pain questions are shown in Table 3.
Biomechanical outcome measures
Both groups demonstrated increased force under the midfoot
when wearing their respective orthoses compared to the shoe-
only condition (FFO=mean change 10.7 % BW [SD 6.6 %];
sham=mean change 4.4 % BW [SD 6.3 %]), yielding a group
mean difference of 6.3 % BW (95 % CI 1.7 to 10.9). Evaluation
of the peak hindfoot kinematics demonstrated that the FFO
inverted the hindfoot relative to the shoe-only condition
(mean=0.7°, 95 % CI −0.1° to 1.5°), whereas the sham device
everted the foot more (mean=−0.3°, 95 % CI −1.7° to +1.0°),
yielding a groupmean difference of 1.0° (95%CI−0.5° to 2.6°).
Discussion
The present study aimed to examine the role of a commercial-
ly available and commonly used treatment for midfoot OA
and to assess whether a fully powered RCT is feasible. A
future RCT powered to fully evaluate the effectiveness of
FFOs in treating painful midfoot OA appears to be achievable
based on observed recruitment, adherence, retention, blinding
and the ability to detect small clinical differences between the
orthoses intervention and sham groups.
Feasibility outcomes
In physical devices, trials adherence in different treatment
arms may explain clinical response. After 12 weeks, those in
the sham group showed greater adherence than the FFO
group, although a high proportion (93 % sham, 78 % FFO)
of both met the minimal predefined adherence threshold. The
difference may be due to the immediate comfort of the thinner
sham device and the ability to accommodate them within in a
wider variety of footwear (including slippers), compared to
the FFO, which may have been less comfortable and more
difficult to accommodate in a variety of shoes.
Blinding in physical device trials is rarely evaluated despite
the potential visible differences between the intervention and
placebo/shamdevices [20]. In this study of participantswhowere
naïve to orthoses, only one quarter of the group correctly identi-
fied the device, suggesting that blinding can be achieved where
care is taken to ensure that devices are similar in appearance.
Recruitment took place over a pre-planned 8-month period,
where an average of 15 potential participants were screened and
4.6 participants were recruited per month. Recruitment for a
larger RCT would be feasible using a conservative estimate of
3.5 patients per month per centre (a 25% reduction), employing
a longer recruitment window and multiple recruiting centres.
Clinical outcomes
In this feasibility study, a double-blind randomised controlled
protocol was employed to minimise the influence of confound-
ing factors and systematic bias. There was a trend towards the
FFO group reporting a small improvement in pain and function
compared to the sham group. These improvements were slightly
Table 1 Baseline demographics and clinical characteristics of participants
Total group (n=37) Functional foot orthoses (n=19) Sham intervention (n=18)
Age (years) 58.4 (11.6) 60.5 (10.4) 56.2 (12.6)
Gender (female) 26 (70.3 %) 15 (78.9 %) 11 (61.1 %)
Body mass index (kg/m2) 29.5 (4.5) 31.2 (4.5) 27.7 (3.9)
Right foot affected (proportion) 20 (54.1 %) 11 (57.9 %) 9 (50.0 %)
Values are reported as mean (SD) unless otherwise stated
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smaller than our predefined minimal for clinically worthwhile
improvement in pain (NRS=1.5 point reduction) and function
(MFPDI=≥3 point reduction). Notably, while the FFO group
demonstrated a 3.6 point reduction in subjective function
(MFPDI) which exceeded the predefined minimally important
difference, the sham group also demonstrated a 2.2-point reduc-
tion. A greater number of participants (36 %) in the FFO group
reported improvement (using the PGIC scale) compared to the
sham group. With improvements reported in both treatment
arms, detection of placebo or natural history effects could only
have been differentiated from the treatment effect by including a
no-treatment arm. Overall, however, the reported improvements
in participants’ pain, function and PGIC do support the hypoth-
esis that the FFO may provide short-term clinical benefits. The
clinical findings in this study are also consistent with previous
studies examining the effect of foot orthoses on pain and func-
tion in midfoot OA patients [12, 13]. Taken together, these find-
ings suggest that powered RCTs are now required.
The clinical improvements in both the FFO and sham
groups are consistent with previous RCTs [30–35], suggesting
there may be treatment benefit with some sham interventions
due to the materials and manufacturing used not being entirely
inert mechanically and therefore mediating foot pressures
[20]. The specific sham intervention used in this study had
minimal effect on midfoot forces and hindfoot kinematics
and appears to be an adequate mechanical control for a defin-
itive study but the interaction warrants exploration in a defin-
itive RCT.
Biomechanical outcome measures
To explore the effect of the different orthoses treatments in this
study, a discrete number of biomechanical outcomes were in-
vestigated after 12 weeks of treatment to allow for acclimatisa-
tion and clinical use. The FFO intervention inverted the
hindfoot by a small amount, whereas the sham allowed the
hindfoot to evert by a similar magnitude. These findings are
consistent with previous research that reported reduced
hindfoot eversion when walking with three-quarter length
FFOs, compared to full length or no orthoses [12]. There was
an apparent between-group difference in force at the midfoot,
with the FFO group yielding double the increase in force com-
pared to sham group. These findings are corroborated in the
literature, which suggests that increased midfoot pressures
[11] and forces [29, 36] are observed with FFOs. The current
biomechanical findings indicate a trend towards a different bio-
mechanical effect for the two orthoses, with the FFOs appearing
to restrict hindfoot motion while supporting the midfoot.
Limitations
We recognise a number of limitations. The baseline matching
for BMI and gender was relatively weak, and a future, largerTa
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study will need to manage such balance through stratification in
the randomisation. Second, differences in pain or related func-
tional scores did not meet pre-specified minimally important
differences, and ordinal scales (NRS and MFPDI) may not be
adequately sensitive to detect change over time. Future studies
should supplement these subjective measures with objective
measures of function such as kinematics and force, as was done
in the present study and should consider using novel ap-
proaches such as activity monitoring that may bemore sensitive
in detecting changes in impairment and pain related function.
Conclusion
The NICE clinical OA guidelines [14] suggest the use of orthoses
as an adjunct treatment, although there is a lack of RCTevidence
for their use in painful foot OA. Our present study shows that
conducting a large trial is feasible in terms of recruitment,
blinding, adherence and treatment effect. This study provides
some evidence on how to detect patient improvement and that
there is a measureable clinical difference between the FFO and
sham groups that justifies further investigation with a fully
powered RCT. To examine whether some of the improvement
demonstrated in the sham group was associated with natural im-
provement, we would recommend that the definitive trial include
a third, active-monitoring armwith no planned treatment, in order
to better understand the placebo effect. This feasibility study sug-
gests that implementation of a definitive RCT to evaluate the
effectiveness of FFO for painful midfoot OA is achievable.
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